Project Details
Description
BRAF V600 mutation testing to determine eligibility for PBS access to Braftovi (encorafenib) in patients with metastatic colorectal cancer (stage 4).
Status | Finished |
---|---|
Effective start/end date | 3/02/20 → 17/04/20 |
Prizes
-
2022 Macquarie Business School Impact Competition, Improving Health and Spending Money Wisely: Evaluating Medical Tests, Devices, Procedures for the Australian Government
Hoyle, Martin (Recipient), Cutler, Henry (Recipient), Parkinson, Bonny (Recipient), Norman, Alicia (Recipient), Jeet, Varinder (Recipient), Seil, Elizabeth (Recipient), Sharma, Rajan (Recipient), Song, Rachel (Recipient), Ahumada Canale, Antonio (Recipient), Rana, Rezwanul (Recipient), Mumford, Virginia (Recipient) & Amin, Janaki (Recipient), 2022
Prize